Pages
Tuesday, July 31, 2018
Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease
Monday, July 30, 2018
Willy Burgdorfer’s statement about tick attachment time
—Willy Burgdorfer
How long does a tick have to be on you...
Wednesday, July 11, 2018
Found a tick on you and want it tested for disease? TestMyTick
Tulsa Dermatologist Creates Test My Tick Kit
TestMyTick.com
About Us
We've partnered with the preeminent Laboratory of Medical Zoology (LMZ), to offer a battery of tests to detect disease-causing microbes in ticks. Your tick can be tested for over 20 different disease causing organisms that ticks can carry (like Lyme disease, Rocky Mountain Spotted Fever, and newly discovered diseases like Powassan, Heartland, and Colorado Tick Fever Virus). We now share that data as part of Tick-Borne Disease Network passive surveillance that we hope will provide unprecedented insights to who is being bitten by ticks, when they get bitten, and what pathogens those ticks are carrying. We encourage everyone to SAVE THE TICKS! ....for Testing!
LMZ-
Laboratory of Medical Zoology (LMZ)
Fernald Hall, University of Massachusetts
Amherst, MA 01003
http://www.tickdiseases.org/
Unusually High Levels of HHV Found in the Brains of Those With Alzheimer's
Tuesday, July 10, 2018
WSJ Article- New Effort for Lyme Disease Vaccine Draws Early Fire
New Effort for Lyme Disease Vaccine Draws Early Fire
By
Sumathi Reddy
Updated July 9, 2018 3:48 p.m. ET
Efforts to bring a vaccine for Lyme disease to the market have run aground amid heated debate over the years.
Now, a European company is in the early stages of creating a vaccine for the increasingly common tick-borne disease. Lyme disease patient-advocacy groups—who disagree with the protocols used by most doctors for the diagnosis andtreatment of Lyme disease—are already raising concerns.
Saturday, July 7, 2018
Study of NLY01 at Hopkins: Stops Parkinson's disease progression
July 7, 2018
Experimental Drug Halts Parkinson's Progression, Study Says; Johns Hopkins University researchers
An experimental drug developed by Johns Hopkins University researchers appears to slow down the progression of Parkinson's disease and its symptoms in mice,
The researchers said that the drug called NLY01 has been proven in studies to block the degradation of brain cells that is the leading cause of Parkinson's disease. The treatment has been used in the past to treat diabetes, researchers said in the university statement.
The study's results, which were published last month in the journal Nature Medicine, reported that NLY01 works by binding to glucagon-like peptide-1 receptors on the surface of certain cells. Similar drugs are used widely in the treatment of type 2 diabetes to increase insulin levels in the blood, the university statement said.
"NLY01 also prolongs the life and reduces the behavioral deficits and neuropathological abnormalities in the human A53T α-synuclein (hA53T) transgenic mouse model of α-synucleinopathy-induced neurodegeneration,"
Parkinson's disease is a progressive disorder of the nervous system that affects about 1 million people in the United States and 10 million worldwide,
"It is amazingly protective of target nerve cells," Ted Dawson, director of the Institute for Cell Engineering at the Johns Hopkins University School of Medicine, said in the university's statement.
The drug is expected to move to clinical trials later this year, the statement said. Dawson added that if planned clinical trials are successful in humans, it could be one of the first treatments to directly target the progression of Parkinson's disease, not just the muscle rigidity, spasmodic movements, fatigue, dizziness, dementia, and other symptoms of the disorder.
Dawson cautioned that NLY01 must still be tested for safety as well as effectiveness in people but based on the safety profile of other similar drugs, he does not anticipate any major hurdles on the way to human trials.
The researcher added that they are hopeful that NLY01 could, in a relatively short period of time, make an impact on the lives of those with Parkinson's, the university statement said.
Friday, July 6, 2018
Eco researchers discuss Lyme
Tuesday, July 3, 2018
Press release about a vaccine against Lyme disease
Valneva is now finalizing the detailed Phase 2 protocol and, subject to requisite regulatory approvals, expects to enter Phase 2 clinical development by the end of 2018.